
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen demonstrates a positive financial outlook, primarily driven by its robust portfolio of neurodegenerative treatments and strategic collaborations, with its multiple sclerosis franchise still contributing 40% of total revenue in 2025. The performance of Leqembi, which commands over 60% market share in the expanding anti-amyloid sector, reflects steady sequential growth, and its differentiated administration flexibility enhances its competitive position. Additionally, the successful launch of Zurzuvae is evident, with revenue surpassing expectations at approximately $65.7 million in 4Q25, underlining strong demand and reinforcing confidence in Biogen's market trajectory.
Bears say
Biogen's stock outlook is negatively influenced by anticipated declines in total revenue, projected to decrease by about $500 million in FY26, largely due to mounting competition and pressure on its multiple sclerosis franchise, which was crucial in contributing 40% of total revenue in 2025. The company has also issued non-GAAP EPS guidance for FY26 that falls below consensus expectations, indicating potential challenges in meeting financial targets amidst a competitive landscape. Furthermore, slower-than-expected growth of newer products like Leqembi, Skyclarys, and Zurzuvae adds to concerns regarding revenue sustainability and emphasizes the absence of immediate revenue drivers as critical risks moving forward.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares